For patients already taking simvastatin (10, 20, or 40 mg daily) with or without sitagliptin 100 mg daily, JUVISYNC may be initiated at the dose of 100 mg sitagliptin and the dose of simvastatin ...

Sitagliptin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes. The Food and Drug Administration has given Biocon Ltd.’s wholly owned ...

The FDA has approved a fixed-dose combination tablet consisting of sitagliptin and simvastatin, two drugs previously approved for type 2 diabetes and hypercholesterolemia. The new drug will be ...

Unichem has obtained tentative approval from the Food and Drug Administration for sitagliptin tablets in dosage strengths of 25 mg, 50 mg, and 100 mg The medication is a generic of Merck Sharpe and ...

The FDA has notified healthcare professional and patients of revisions to the prescribing information for Merck’s Januvia (sitagliptin tablets) and Janumet (sitagliptin/metformin tablets) to include ...

First combination drug to treat type 2 diabetes and high cholesterol in one tablet The U.S. Food and Drug Administration today approved Juvisync (sitagliptin and simvastatin), a fixed-dose combination ...

Adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes who are not adequately controlled on metformin or sitagliptin alone or in patients already being treated with ...

Zituvimet XR is supplied in 3 extended-release tablet strengths. The Food and Drug Administration (FDA) has approved Zituvimet XR (sitagliptin and metformin hydrochloride) extended-release tablets as ...

Merck concerned for diabetes patients in B.C., in light of B.C. Pharmacare announcement of decision to de-list sitagliptin products (Januvia® and Janumet®) VANCOUVER, Aug. 5, 2014 (Canada NewsWire via ...

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- In a new post-hoc analysis presented for the first time at the American Diabetes Association (ADA) 70 th Annual Scientific Sessions, significantly more ...

Objectives: To compare 1-year clinical outcomes and cost efficiency of treating adults with type 2 diabetes mellitus (T2DM) with canagliflozin (300 mg/day) or sitagliptin (100 mg/day), both added on a ...